Instruction for use: Mazipredonee (Mazipredoneum)

Pharmacological group

Glucocorticosteroids

Nosological classification (ICD-10)

A48.3 Toxic shock syndrome

Bacteria-nomic shock, Infectious-toxic shock, intoxication syndrome, Toxic-infectious shock, Toxic shock, Chronic intoxication at diseases of the gastrointestinal tract, Chronic intoxication with gastrointestinal infections, endotoxin shock

E05.5 Thyroid crisis or coma

thyrotoxic crisis, hypothyroid coma, thyrotoxic crisis

E27.9 Adrenal disease, unspecified

Adrenal Dysfunction, Sympathic-adrenal crises

G93.6 Edema of the brain

Intraoperative cerebral edema, Cerebral edema, Post-traumatic swelling of the brain, Brain edema associated with radiation therapy, Brain edema associated with head trauma, Post-traumatic cerebral edema, Edema of the brain in poisoning

J45 Asthma

Asthma physical effort, status asthmaticus, Bronchial asthma, Asthma lung flow, Bronchial asthma with obstruction of sputum discharge, Bronchial asthma heavy currents, Bronchial asthma physical effort, hypersecretory asthma, Hormone-dependent form of bronchial asthma, Relief of asthma attacks in bronchial asthma, Non-allergic asthma, nocturnal asthma, Exacerbation of asthma, Asthma attacks, Endogenous forms of asthma, Night asthma, Cough with bronchial asthma

J46 Status asthmaticus

Asthmatic attack, status asthmaticus, Bronchospasm in bronchial asthma

K72.0 Acute and subacute liver failure

Lightning-fast hepatitis, Hepatitis acute, Hepatic failure acute and subacute

K72.9 Hepatic insufficiency, unspecified

Latent hepatic encephalopathy, Acute liver failure, Liver failure, Hepatic precoma, Acute hepatic-renal failure

M06.9 Other specified rheumatoid arthritis

Rheumatoid arthritis,Pain syndrome in rheumatic diseases, Pain in rheumatoid arthritis, Inflammation in rheumatoid arthritis, Degenerative forms of rheumatoid arthritis, Children's rheumatoid arthritis, Exacerbation of rheumatoid arthritis, Acute articular rheumatism, Rheumatic arthritis, Rheumatic polyarthritis, Rheumatoid arthritis, Rheumatic polyarthritis, Rheumatoid arthritis, Rheumatoid arthritis of active course, Rheumatoid arthritis, Rheumatoid polyarthritis, Acute rheumatoid arthritis, Acute rheumatism

M32 Systemic lupus erythematosus

Lupus erythematosus red disseminated, Disseminated lupus erythematosus, Chronic lupus erythematosus

R57.0 Cardiogenic shock

cardiogenic shock

R57.8 Other types of shock

Blood transfusion shock, Obstructive shock, Circulatory shock

R57.8.0 * Burn shock

Pain shock with burns, Burn shock

T49.8 Poisoning by other topical agents

T78.2 Anaphylactic shock, unspecified

Anaphylactic shock, Anaphylactoid reaction, Anaphylactic shock, Anaphylactic reactions, Anaphylactic shock to drugs

T78.4 Allergy, unspecified

Allergic reactions to insulin, Allergic reactions to insect stings, Allergic reactions similar to systemic lupus erythematosus, Allergic diseases, Allergic diseases of mucous membranes, Allergic diseases and conditions resulting from increased release of histamine, Allergic diseases of mucous membranes, Allergic symptoms, Allergic symptoms in the mucous membranes, Allergic reactions, Allergic reactions caused by insect bites, Allergic reactions, Allergic conditions, Allergic laryngeal edema, allergopathy, allergic conditions, Allergy, House dust allergy, Anaphylaxis, Cutaneous reactions to medications, Skin reaction to insect stings, Cosmetic allergy, Drug allergy, Acute allergic reaction, Laryngeal edema allergic genesis and background radiation, Food and drug allergy

T79.4 Traumatic shock

Hemorrhagic shock, Crush syndrome, hemorrhagic shock, postoperative shock, post-traumatic shock, traumatic shock, hemorrhagic shock and encephalopathy syndrome

T81.1 Shock during or after the procedure, not elsewhere classified

Operating shock, Postoperative shock, Operational shock

Code CAS13085-08-0

Characteristics

Hormonal remedy (glucocorticoid). Water-soluble synthetic derivative of prednisolone.

Pharmacology

Pharmacological action - anti-inflammatory, antiallergic, immunosuppressive, anti-shock, glucocorticoid.

Interacts with specific cytoplasmic receptors, inhibits phospholipase A2, reduces the synthesis of leukotrienes and PG (prostaglandins). Promotes the involution of lymphoid tissue, reduces the production of antibodies. Stimulates cardiac activity, restores the sensitivity of adrenergic receptors to catecholamines, strengthens vasopressor effects, delays sodium and water.

When applied to the skin, it is slowly absorbed and has a local and systemic effect: it narrows the vessels of the skin, reduces the permeability of the capillaries, stabilizes the proliferation of epidermal cells and fibroblasts, depresses the chemotaxis of cells of the monocyte-macrophage system, reduces the number of basophils, disrupts the degranulation of mast cells.

With the / in the introduction is distributed in the body for 0.5 h, T1 / 2 - 3.3 h.

Application of Mazipredone

Shock (burn, traumatic, operational, toxic, cardiogenic) with ineffectiveness of other therapy; Allergic reactions (acute, severe forms), hemotransfusion shock, anaphylactic shock; Anaphylactoid reactions; Cerebral edema (including on the background of a brain tumor or associated with surgical intervention, radiation therapy or head trauma); Bronchial asthma (severe form), asthmatic status; Systemic connective tissue diseases (systemic lupus erythematosus, rheumatoid arthritis); Acute adrenal insufficiency; Thyrotoxic crisis; Acute hepatitis, hepatic coma; Poisoning with cauterizing fluids (reducing inflammation and preventing cicatricial narrowing).

Contraindications

Hypersensitivity (for short-term systemic use according to vital indications). With long-term treatment: peptic ulcer of the stomach or duodenal ulcer in the acute phase, Isenko-Cushing syndrome, diabetes mellitus at the stage of decompensation, severe osteoporosis, psychosis, severe arterial hypertension, acute infectious diseases, tuberculosis (without appropriate chemotherapy), vaccination period (increased risk The occurrence of infections, especially in children - including measles, herpes), an increased risk of thromboembolism, glaucoma, systemic mycoses, decompensated liver cirrhosis with portal hypertension syndrome And, decompensated heart failure, terminal renal failure with a syndrome of renal osteodystrophy, pregnancy, breast-feeding; The period of neonatal (due to the presence of benzyl alcohol).

pregnancy and lactation

Contraindicated in pregnancy. At the time of treatment should stop breastfeeding.

Side effects

The frequency of development and the severity of side effects depend on the duration of the application, the amount of the dose used and the possibility of observing the circadian rhythm of the appointment.

On the part of the endocrine system and metabolism: Itenko-Cushing's syndrome, steroid diabetes, glucosuria, obesity, atrophy of the adrenal cortex, menstrual cycle disorders, negative nitrogen balance.

From the cardiovascular system and blood (hematopoiesis, hemostasis): arterial hypertension, vasculitis, leukocytosis.

From the nervous system and sensory organs: sleep disorders, psychosis, steroid cataract.

On the part of the digestive tract: erosive and ulcerative lesions of the gastrointestinal tract.

From the musculoskeletal system: osteoporosis, steroid myopathy, reduction of muscle mass.

On the part of the skin: slowing down the processes of wound healing, itching, rash, dryness and atrophy of the skin, hypopigmentation, hypertrichosis, ecchymosis.

Other: fluid retention, decreased resistance to infections, withdrawal syndrome, hypokalemia, hypocalcemia.

Interaction

Weaken the effect of antidiabetics, intensify - anticoagulants, cardiac glycosides (including toxic), ulcerogenicity of NSAIDs (nonsteroidal anti-inflammatory drugs), risk of hypokalemia in the treatment of amphotericin B, laxatives, diuretics. Etakrinovaya acid increases the likelihood of bleeding in the gastrointestinal tract, the induction of microsomal oxidation (phenobarbital, diphenhydramine, phenytoin, rifampicin, etc.) level glucocorticoid activity, some antimalarial drugs, estrogens, methandienone - strengthen it, the latter, in addition, Reduces the severity of certain complications (osteoporosis, negative nitrogen balance).

Routes of administration

In / in (intravenously) (struino slowly or drip), in / m (intramuscularly).

Precautions

Taking into account circadian rhythm of endogenous secretion of HA, the main dose of the drug should be administered in the morning hours. Discontinue treatment should be gradual, first reducing the dose taken in the evening and afternoon. Regular blood pressure control, cellular composition of peripheral blood, blood glucose level and electrolyte content are mandatory. Elderly and weakened patients with prolonged treatment showed an additional appointment of anabolic steroids.